eslicarbazepine

03/01/2018 - "Areas covered: We performed a systematic literature search in electronic databases (MEDLINE database, Cochrane Central Register of Controlled Trials, Excerpta Medica dataBASE) using a combined search strategy including the following keywords: eslicarbazepine, epilepsy and seizure. "
08/18/2023 - "The medical records of 164 patients with epilepsy taking eslicarbazepine in our center were analyzed. "
01/01/2021 - "Complex effects of eslicarbazepine on inhibitory micro networks in chronic experimental epilepsy."
04/01/2015 - "Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy."
11/02/2010 - "Update on treatment of partial onset epilepsy: role of eslicarbazepine."

10/01/2018 - "Eslicarbazepine is a novel anti-epileptic agent indicated for the treatment of partial-onset seizures. "
10/01/2018 - "Intentional overdose of the novel anti-epileptic drug eslicarbazepine presenting with recurrent seizures and ventricular dysrhythmias."
12/01/2010 - "Eslicarbazepine can be prescribed in Europe for partial seizures, but not in the US. "
04/15/2010 - "Eslicarbazepine is an effective and reasonably well-tolerated adjunct in patients with suboptimal control of their partial seizures."
11/01/2021 - "Eslicarbazepine-induced severe hyponatremia resulted in generalized tonic-clonic seizure."

04/16/2021 - "Eslicarbazepine monotherapy in patients with newly diagnosed partial epilepsy, both in the general population and in the population over 65 years old, is effective and safe in routine clinical practice. "
04/16/2021 - "To evaluate the effectiveness of eslicarbazepine as initial monotherapy in patients with newly diagnosed partial epilepsy in routine clinical practice. "
06/01/2020 - "We report a patient with focal epilepsy successfully treated with eslicarbazepine without exacerbation of porphyria."
06/01/2020 - "Eslicarbazepine for focal epilepsy and acute intermittent porphyria."
11/01/2016 - "A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy."

11/01/2020 - "This study aims to evaluate the impact of eslicarbazepine (ESL) as add-on therapy on the sleep microstructure in temporal lobe epilepsy (TLE). "
11/01/2020 - "Effects of eslicarbazepine as add-on therapy on sleep architecture in temporal lobe epilepsy: results from "Esleep" study."
05/06/2011 - "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."
06/28/2010 - "In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiepileptic drugs after a single seizure; monotherapy for partial epilepsy using carbamazepine, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, sodium valproate, or topiramate; addition of second-line drugs for drug-resistant partial epilepsy (allopurinol, eslicarbazepine, gabapentin, lacosamide, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide); antiepileptic drug withdrawal for people with partial or generalised epilepsy who are in remission; behavioural and psychological treatments for partial or generalised epilepsy (biofeedback, cognitive behavioural therapy (CBT), educational programmes, family counselling, relaxation therapy (alone or plus behavioural modification therapy, yoga); and surgery for drug-resistant temporal lobe epilepsy ( lesionectomy, temporal lobectomy, vagus nerve stimulation as adjunctive therapy)."

08/18/2023 - "The study shows that eslicarbazepine-induced hyponatremia is usually mild and asymptomatic. "
08/18/2023 - "Eslicarbazepine-induced hyponatremia: A retrospective single-center real clinical practice study."
11/01/2021 - "Although eslicarbazepine is an anti-seizure medication, it may result in seizure worsening if its use is complicated by severe hyponatremia, even long time after commencing this medication. "
01/01/2018 - "Because the first occurrence of adverse events or hyponatremia were also not significantly related to eslicarbazepine exposure, dose adjustment using plasma eslicarbazepine concentrations is not supported."
08/18/2023 - "The study investigated the prevalence of hyponatremia in patients with epilepsy who were treated with eslicarbazepine. "